Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Prof Jackie Boultwood and Dr Andrea Pellagatti, who have been awarded a project grant from Leuka – a leading leukaemia research charity. Their work will focus on Chronic myelomonocytic leukaemia (CMML), a blood cancer with a poor prognosis and limited treatment options.

Characterization of pluripotency of induced pluripotent stem cells (iPSCs) by fluorescent immunohistochemistry. © Jackie Boultwood and Andrea Pellagatti
Characterization of pluripotency of induced pluripotent stem cells (iPSCs) by fluorescent immunohistochemistry.

The team aim to generate new, cell-based models of CMML, so that they can study the causes of disease and identify new treatment options. They will create induced pluripotent stem cells (iPSCs) – cells that have the ability to become many different cells in the body – from the bone marrow of healthy volunteers, and from patients with CMML harbouring the specific gene mutations known to commonly co-occur in this disorder. They will then go on to use CRISPR/Cas9 genome editing technology to introduce common gene mutations found in CMML to generate disease models. They will use these models to tease apart the mechanisms underlying CMML, as well as using them as a platform for high throughput drug screening. Learn more about the team's research.

The research is one of two project grants awarded by Leuka in this round.

Discussing the recently funded research, Leuka Chief Executive Olive Boles said, “We are incredibly excited by the research these projects will be undertaking. With 26 people diagnosed with leukaemia each day, it is imperative that we support research that can be translated into clinical trials and treatments. Both of these projects have the potential to do just that to help improve the lives of leukaemia and blood cancer patients around the UK.”

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Professor Higgs' major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

Intensive blood glucose control for people with type 2 diabetes when they are first diagnosed reduces diabetic complications and prolongs life

The study, which tracked volunteers for up to 44 years, showed that the benefits of early intensive blood glucose control can persist for decades.